The specter of generic challenges has long loomed over copyright’s blockbuster drug, Sildenafil, triggering questions about the outlook of connected pharmaceutical investments. While initial periods saw substantial gains, the exclusivity end has allowed the way for cheaper copies, potentially lowering revenue and posing a significant hazard for … Read More